Key Points
- CEO Ying Luo sold 10,136 shares of Gyre on May 6 at an average price of $8.04 for $81,493, after also selling 179 shares on May 5, leaving her with 2,565,226 shares (a 0.39% reduction).
- Gyre missed quarterly expectations, reporting EPS of -$0.10 (vs. -$0.06 est.) and revenue of $22.52M (vs. $31.61M est.), and the stock traded down about 12.1% to open at $7.07.
- The company has a market cap of roughly $686M, a high P/E of 707.71, and mixed analyst coverage with an average rating of "Hold" and an average price target of $17.00.
Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) CEO Ying Luo sold 10,136 shares of the firm's stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $8.04, for a total transaction of $81,493.44. Following the completion of the sale, the chief executive officer owned 2,565,226 shares of the company's stock, valued at $20,624,417.04. The trade was a 0.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.
Ying Luo also recently made the following trade(s):
- On Tuesday, May 5th, Ying Luo sold 179 shares of Gyre Therapeutics stock. The stock was sold at an average price of $8.01, for a total transaction of $1,433.79.
Gyre Therapeutics Trading Down 12.1%
Shares of GYRE stock opened at $7.07 on Friday. Gyre Therapeutics, Inc. has a 1 year low of $6.57 and a 1 year high of $11.78. The firm's 50 day moving average is $7.58 and its 200-day moving average is $7.69. The firm has a market capitalization of $685.75 million, a price-to-earnings ratio of 707.71 and a beta of 2.03.
Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.04). Gyre Therapeutics had a net margin of 4.31% and a return on equity of 10.85%. The company had revenue of $22.52 million during the quarter, compared to analyst estimates of $31.61 million. On average, equities research analysts forecast that Gyre Therapeutics, Inc. will post -0.18 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in GYRE. State of Alaska Department of Revenue bought a new position in shares of Gyre Therapeutics in the 3rd quarter worth $38,000. Bank of America Corp DE grew its stake in shares of Gyre Therapeutics by 28.8% during the second quarter. Bank of America Corp DE now owns 6,277 shares of the company's stock worth $46,000 after purchasing an additional 1,402 shares during the period. JPMorgan Chase & Co. increased its holdings in Gyre Therapeutics by 84.6% in the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company's stock valued at $47,000 after purchasing an additional 2,961 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Gyre Therapeutics by 77.8% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company's stock valued at $54,000 after buying an additional 3,244 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new position in Gyre Therapeutics in the fourth quarter valued at about $77,000. Institutional investors and hedge funds own 23.99% of the company's stock.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on GYRE shares. Zacks Research lowered Gyre Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Monday, March 16th. Weiss Ratings reiterated a "sell (d)" rating on shares of Gyre Therapeutics in a research report on Thursday, January 22nd. Finally, Wall Street Zen downgraded shares of Gyre Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, March 14th. Two investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, Gyre Therapeutics presently has an average rating of "Hold" and an average price target of $17.00.
Read Our Latest Report on GYRE
Gyre Therapeutics Company Profile
(
Get Free Report)
Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company's proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.
Gyre's preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer's disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
